Manufacturer
L.B.S. LABS LTD PART
Contents
Dexamethasone Na phosphate
Indication
Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; relative adrenocortical insufficiency; primary & secondary adrenocortical insufficiency. Therapy for collagen, rheumatic & skin diseases, pulmonary, blood, GI, eye & endocrine disorders, oedema, neoplastic states. Pre- & post-op support. Adjunct in shock treatment.
Instruction
Administer via IM injection/IV injection/IV infusion/ Intra-synovial & soft tissue inj.
Drug interaction
Reduced effect w/ hepatic enzyme-inducing agents ie, barbiturates, phenylbutazone, phenytoin, rifampicin. Increased effect w/ antithyroid agents, oestrogens, OCs. Decreased anticoagulant effects. Seizures w/ cyclosporin. Increased risk of GI ulceration or haemorrhage w/ anticoagulants, heparin, streptokinase, urokinase, alcohol, NSAIDs ie, aspirin. Severe hypokalaemia w/ K-depleting diuretics eg, thiazides, frusemide or ethacrynic acid, carbonic anhydrase inhibitors or amphotericin B. Potentiated activity of digitalis glycoside & nondepolarising neuromuscular-blocking agents due to glucocorticoid-induced hypokalemia. Reduced efficacy on serum K conc of K supplements & K-sparing diuretics. Increased blood glucose conc.
L.B.S. LABS LTD PART
Contents
Dexamethasone Na phosphate
Indication
Replacement therapy for acute adrenocortical insufficiency eg, Addison's disease, bilateral adrenalectomy; relative adrenocortical insufficiency; primary & secondary adrenocortical insufficiency. Therapy for collagen, rheumatic & skin diseases, pulmonary, blood, GI, eye & endocrine disorders, oedema, neoplastic states. Pre- & post-op support. Adjunct in shock treatment.
Instruction
Administer via IM injection/IV injection/IV infusion/ Intra-synovial & soft tissue inj.
Drug interaction
Reduced effect w/ hepatic enzyme-inducing agents ie, barbiturates, phenylbutazone, phenytoin, rifampicin. Increased effect w/ antithyroid agents, oestrogens, OCs. Decreased anticoagulant effects. Seizures w/ cyclosporin. Increased risk of GI ulceration or haemorrhage w/ anticoagulants, heparin, streptokinase, urokinase, alcohol, NSAIDs ie, aspirin. Severe hypokalaemia w/ K-depleting diuretics eg, thiazides, frusemide or ethacrynic acid, carbonic anhydrase inhibitors or amphotericin B. Potentiated activity of digitalis glycoside & nondepolarising neuromuscular-blocking agents due to glucocorticoid-induced hypokalemia. Reduced efficacy on serum K conc of K supplements & K-sparing diuretics. Increased blood glucose conc.
Inquiry - Lodexa Injection